Better Early Molecular Response and relapse free survival in Newly Diagnosed Core Binding Factor Leukemia
Compared to idarubicin, GO when added to FLAG based frontline induction/consolidation regimen results in better early molecular responses and improved relapse free survival in CBF AML. Click and hear Gautam Borthakur present the new data.
MEST SETE MEDtalks
ASH 2018: Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients – in Real-World Clinical Practice Se hele webinar
In this MEDtalk John Gribben, Professor, MD DSc, Barts Cancer Institute, University of London, present the key data from MURANO study about treatment of relapsed/Refractory CLL.